Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AADAT | Q8N5Z0 | 1/20 | 0.33 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | BRD9 | Q9H8M2 | 11/20 | 0.32 |
| ▸ | BRD7 | Q9NPI1 | 11/20 | 0.32 |
| ▸ | BRD4 | O60885 | 6/20 | 0.32 |
| ▸ | BRD2 | P25440 | 5/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | TAF1 | P21675 | 2/20 | 0.31 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.31 |
| ▸ | ACVR1 | Q04771 | 2/20 | 0.31 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.31 |
| ▸ | CECR2 | Q9BXF3 | 2/20 | 0.31 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.31 |
| ▸ | BPTF | Q12830 | 1/20 | 0.31 |
| ▸ | TAF1L | Q8IZX4 | 1/20 | 0.31 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.31 |
| ▸ | ATAD2B | Q9ULI0 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 2/20 | 0.31 |
| ▸ | TYK2 | P29597 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL613041 | 0.86 | CDK1 (0.41) | GAATYK2ALDH1A1HPGD | |
| SCHEMBL31470158 | 0.86 | CDK1 (0.41) | GAATYK2ALDH1A1HPGD | |
| SCHEMBL612105 | 0.82 | ALDH1A1 (0.34) | AADATGAAACVR1TSHRALDH1A1 | |
| SCHEMBL31470105 | 0.81 | TLR7 (0.38) | GAATYK2ALDH1A1HPGD | |
| SCHEMBL611801 | 0.74 | GRM2 (0.36) | ALDH1A1 | |
| SCHEMBL8279161 | 0.73 | PIM1 (0.45) | — | |
| SCHEMBL7903152 | 0.72 | HIF1A (0.33) | GAATSHRALDH1A1HPGD | |
| SCHEMBL612542 | 0.71 | GRM2 (0.34) | ALDH1A1 | |
| SCHEMBL7896811 | 0.70 | KDM4E (0.37) | KCNH2GAAALDH1A1HPGDCYP2D6 | |
| SCHEMBL7895858 | 0.68 | HPGD (0.34) | GAATSHRALDH1A1HPGDCYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2379510-B1 | QUINAZOLINONE COMPOUNDS | PRANA BIOTECHNOLOGY LTD (AU) | 2016-10-26 | — | — | EP | disclosed |
| EP-2379510-B1 | QUINAZOLINONE COMPOUNDS | PRANA BIOTECHNOLOGY LTD (AU) | 2016-10-26 | — | — | EP | disclosed |
| US-20150359796-A1 | QUINAZOLINONE COMPOUNDS | PRANA BIOTECHNOLOGY LIMITED (AU) | 2015-12-17 | — | — | US | disclosed |
| US-20150359796-A1 | QUINAZOLINONE COMPOUNDS | PRANA BIOTECHNOLOGY LIMITED (AU) | 2015-12-17 | — | — | US | disclosed |
| US-9145375-B2 | Quinazolinone compounds | PRANA BIOTECHNOLOGY LIMITED (AU) | 2015-09-29 | — | — | US | disclosed |
| US-9145375-B2 | Quinazolinone compounds | PRANA BIOTECHNOLOGY LIMITED (AU) | 2015-09-29 | — | — | US | disclosed |
| US-20150025072-A1 | QUINAZOLINONE COMPOUNDS | PRANA BIOTECHNOLOGY LIMITED (AU) | 2015-01-22 | — | — | US | disclosed |
| US-20150025072-A1 | QUINAZOLINONE COMPOUNDS | PRANA BIOTECHNOLOGY LIMITED (AU) | 2015-01-22 | — | — | US | disclosed |
| US-8889695-B2 | Quinazolinone compounds | PRANA BIOTECHNOLOGY LIMITED (AU) | 2014-11-18 | — | — | US | disclosed |
| US-8889695-B2 | Quinazolinone compounds | PRANA BIOTECHNOLOGY LIMITED (AU) | 2014-11-18 | — | — | US | disclosed |
| US-20120040980-A1 | QUINAZOLINONE COMPOUNDS | PRANA BIOTECHNOLOGY LIMITED (AU) | 2012-02-16 | — | — | US | disclosed |
| US-20120040980-A1 | QUINAZOLINONE COMPOUNDS | PRANA BIOTECHNOLOGY LIMITED (AU) | 2012-02-16 | — | — | US | disclosed |
| WO-2010071944-A1 | QUINAZOLINONE COMPOUNDS | PRANA BIOTECHNOLOGY LIMITED (AU) | 2010-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150359796-A1 | QUINAZOLINONE COMPOUNDS | PARK7, SNCA, NDUFV2 | AADAT 1189/4885KCNA5 1163/4885KCNH2 1235/4885 |
| US-20150025072-A1 | QUINAZOLINONE COMPOUNDS | PARK7, SNCA, NQO2 | AADAT 916/4885KCNA5 1008/4885KCNH2 1115/4885 |
| US-20120040980-A1 | QUINAZOLINONE COMPOUNDS | PARK7, SNCA, NQO2 | AADAT 916/4885KCNA5 1008/4885KCNH2 1115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.